Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

BACKGROUND: Resistance to endocrine treatment in metastatic breast cancer is a major clinical challenge. Clinical tools to predict both drug resistance and possible treatment combination approaches to overcome it are lacking. This unmet need is mainly due to the heterogeneity underlying both the mec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaminska, Kamila, Akrap, Nina, Staaf, Johan, Alves, Carla L., Ehinger, Anna, Ebbesson, Anna, Hedenfalk, Ingrid, Beumers, Lukas, Veerla, Srinivas, Harbst, Katja, Ehmsen, Sidse, Borgquist, Signe, Borg, Åke, Pérez-Fidalgo, Alejandro, Ditzel, Henrik J., Bosch, Ana, Honeth, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893923/
https://www.ncbi.nlm.nih.gov/pubmed/33602273
http://dx.doi.org/10.1186/s13058-021-01402-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893923/
https://www.ncbi.nlm.nih.gov/pubmed/33602273
http://dx.doi.org/10.1186/s13058-021-01402-1

Ejemplares similares